GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regeneron Pharmaceuticals Inc (BSP:REGN34) » Definitions » Shiller PE Ratio

Regeneron Pharmaceuticals (BSP:REGN34) Shiller PE Ratio : 25.51 (As of Jan. 19, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Regeneron Pharmaceuticals Shiller PE Ratio?

As of today (2025-01-19), Regeneron Pharmaceuticals's current share price is R$71.68. Regeneron Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 was R$2.81. Regeneron Pharmaceuticals's Shiller PE Ratio for today is 25.51.

The historical rank and industry rank for Regeneron Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:

BSP:REGN34' s Shiller PE Ratio Range Over the Past 10 Years
Min: 22.05   Med: 55.21   Max: 2573
Current: 22.05

During the past years, Regeneron Pharmaceuticals's highest Shiller PE Ratio was 2573.00. The lowest was 22.05. And the median was 55.21.

BSP:REGN34's Shiller PE Ratio is ranked better than
72.26% of 137 companies
in the Biotechnology industry
Industry Median: 34.15 vs BSP:REGN34: 22.05

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was R$1.065. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is R$2.81 for the trailing ten years ended in Sep. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Regeneron Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for Regeneron Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regeneron Pharmaceuticals Shiller PE Ratio Chart

Regeneron Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 49.39 44.17 32.61 30.55 32.06

Regeneron Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.96 32.06 33.84 35.34 34.02

Competitive Comparison of Regeneron Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, Regeneron Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regeneron Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regeneron Pharmaceuticals's Shiller PE Ratio falls into.



Regeneron Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regeneron Pharmaceuticals's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=71.68/2.81
=25.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regeneron Pharmaceuticals's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Regeneron Pharmaceuticals's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=1.065/133.0289*133.0289
=1.065

Current CPI (Sep. 2024) = 133.0289.

Regeneron Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201412 0.042 99.070 0.056
201503 0.035 99.621 0.047
201506 0.088 100.684 0.116
201509 0.118 100.392 0.156
201512 0.087 99.792 0.116
201603 0.098 100.470 0.130
201606 0.096 101.688 0.126
201609 0.123 101.861 0.161
201612 0.122 101.863 0.159
201703 0.113 102.862 0.146
201706 0.183 103.349 0.236
201709 0.173 104.136 0.221
201712 0.082 104.011 0.105
201803 0.227 105.290 0.287
201806 0.303 106.317 0.379
201809 0.354 106.507 0.442
201812 0.463 105.998 0.581
201903 0.255 107.251 0.316
201906 0.108 108.070 0.133
201909 0.402 108.329 0.494
201912 0.474 108.420 0.582
202003 0.442 108.902 0.540
202006 0.658 108.767 0.805
202009 0.665 109.815 0.806
202012 0.878 109.897 1.063
202103 0.948 111.754 1.128
202106 2.344 114.631 2.720
202109 1.261 115.734 1.449
202112 1.856 117.630 2.099
202203 0.714 121.301 0.783
202206 0.628 125.017 0.668
202209 1.019 125.227 1.082
202212 0.918 125.222 0.975
202303 0.622 127.348 0.650
202306 0.688 128.729 0.711
202309 0.732 129.860 0.750
202312 0.832 129.419 0.855
202403 0.520 131.776 0.525
202406 1.114 132.554 1.118
202409 1.065 133.029 1.065

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regeneron Pharmaceuticals  (BSP:REGN34) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regeneron Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regeneron Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regeneron Pharmaceuticals Business Description

Address
777 Old Saw Mill River Road, Tarrytown, NY, USA, 10591-6707
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).

Regeneron Pharmaceuticals Headlines

No Headlines